Please assess the completion status of the following clinical trial:

Trial Title: Add-on Pentoxifylline to Losartan Versus Increasing Dose of Losartan on NT-PRO BNP in Type 2 Diabetics With Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age\>30 and age\<70, urinary albumin excretion (UAE) ≥150 mg/24 h~Exclusion Criteria:~* any infectious or malignant diseases, non-diabetic kidney disease, retinal hemorrhage, acute myocardial infarction, uncontrolled hypertension, pregnancy, unable to follow up, hyperthyroidism, baseline serum potassium concentrations ≥5.5 meq/L, glomerular filtration rate (GFR)\<30mL/min/1.73 m and intolerance of pentoxifylline

- Gender: ALL
- Minimum Age: 38 Years
- Maximum Age: 76 Years
- Healthy Volunteers: f

Study Arms:
- pentoxifylline & losartan (Type: ACTIVE_COMPARATOR): pentoxifylline arm took 400 mg pentoxifylline twice daily plus 50mg losartan daily for 12 weeks.
- Losartan (Type: ACTIVE_COMPARATOR): losartan arm took 100mg losartan daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).